Loading
Loading…
Loading…
| # | Company | Rank | Status |
|---|---|---|---|
| 1 | NAAccepted-Finance | NA | Accepted-Finance Please see the list of finalized items |
| 2 | NAAccepted-Finance | NA | Accepted-Finance Please see the list of finalized items |
| 3 | NAAccepted-Finance | NA | Accepted-Finance Please see the list of finalized items |
| 4 | NAAccepted-Finance | NA | Accepted-Finance Please see the list of finalized items |
| 5 | NAAccepted-Finance | NA | Accepted-Finance Please see the list of finalized items |
| Sl No | Description | Qty | Unit | KHANDELWAL LABORATORIES PVT. LTD. L10 | MSN Laboratories Private Limited L24 | NEON LABORATORIES LIMITED L14 | Reliance Life Sciences Pvt Ltd L4 | Intas Pharmaceuticals Ltd. L25 | ALKEM LABORATORIES LTD. L30 | Eisai Pharmaceuticals India Pvt Ltd L16 | UNITED BIOTECH PVT LIMITED L23 | Zuvius Lifesciences Pvt Ltd L18 | Novartis Healthcare Pvt Ltd L38 | Novartis India Ltd. L20 | Aristo pharmaceuticals pvt ltd L9 | Hetero Healthcare Limited L2 | M/s Mankind Pharma Ltd. L27 | Samarth Life Sciences Pvt. Ltd. L26 | Sun Pharma Laboratories Limited L32 | Fresenius Kabi India Pvt Ltd L5 | CADILA PHARMACEUTICALS LIMITED L6 | GLS PHARMA LTD. L17 | Johnson and Johnson Private Limited L37 | GLENMARK PHARMACEUTICALS LIMITED L13 | Cipla Ltd. L12 | BDR PHARMACEUTICALS INTL PVT LTD L35 | EMCURE PHARMACEUTICALS LIMITED L29 | Zydus Lifesciences Limited L36 | NATCO PHARMA LIMITED L34 | Shilpa Medicare Limited L22 | NAPROD LIFESCIENCE PVT LTD L11 | VHB MEDI SCIENCES LIMITED L7 | Del Trade International Private Limited L8 | Celon Laboratories Private Limited L15 | LA RENON HEALTHCARE PRIVATE LIMITED L3 | ROCHE PRODUCTS INDIA PVT LTD L33 | Amneal Healthcare Private limited L19 | M/s Beta Drugs Limited L21 | Macleods Pharmaceuticals Ltd. L1 | Dr Reddys Laboratories Limited L31 | JODAS EXPOIM PRIVATE LIMITED L28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1.001.01 to 1.02- 5-FLUOROURACILE - (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||||||||||||||||||||||||||||||||||||||
| 1.01 | 5-FLUOROURACIL | 1 | 500 MG/10 ML | - | - | - | - | - | - | - | 38,88,540 ₹40,82,967 | - | - | - | - | - | - | - | - | - | - | 40,07,925 ₹42,09,174 | - | - | - | - | - | - | - | - | - | - | - | 32,21,689.5 ₹33,82,006.5 Lowest | - | - | - | - | - | - | - |
| 1.02 | 5-FLUOROURACIL | 1 | 250 MG/5 ML | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5,52,015 ₹5,79,811.5 | - | - | - | - | - | - | - | - | - | - | - | 3,05,370 ₹3,20,638.5 Lowest | - | - | - | - | - | - | - |
| 2.002.01 to 2.02- 5-FLUOROURACIL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||||||||||||||||||||||||||||||||||||||
| 2.01 | 5-FLUOROURACIL | 1 | 500 MG/10 ML | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 2.02 | 5-FLUOROURACIL | 1 | 250 MG/5 ML | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3.003.01 to 3.02- ABEMACICLIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||||||||||||||||||||||||||||||||||||||
| 3.01 | ABEMACICLIB | 1 | 100 MG | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 3.02 | ABEMACICLIB | 1 | 150 MG | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| 4.004.01 to 4.02- BOSUTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||||||||||||||||||||||||||||||||||||||
Tender Value
₹200 Cr
EMD Value
₹5 L
Closing Date
3 Nov 2025, 3:00 pmClosed
Dr Sudeep Gupta, Director, TMC
TMH. Parel
Purchase of Drugs (ONCOLOGY, GROWTH FACTOR, ANTIEMETIC)
2025_TMC_875257_1
TMC/DRG/M/C/Sch.VI/2025/15
Open Tender
Drugs and Pharmaceutical Products
Item Rate
TMH. Parel
Please refer Tender documents.
4 documents required · 4 mandatory
₹0
₹5 L
Yes
Online
5 Aug 2026
29 Aug 2025
4 Nov 2025
29 Aug 2025
3 Nov 2025
15 Sept 2025
29 Aug 2025 - 8 Sept 2025
8 Sept 2025
| Sl No | Description | Qty | Unit | Est. Rate | Est. Amount |
|---|---|---|---|---|---|
| 11.01 to 1.02- 5-FLUOROURACILE - (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||
| 1.01 | 5-FLUOROURACIL | 1 | 500 MG/10 ML | - | - |
| 1.02 | 5-FLUOROURACIL | 1 | 250 MG/5 ML | - | - |
| 22.01 to 2.02- 5-FLUOROURACIL (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||
| 2.01 | 5-FLUOROURACIL | 1 | 500 MG/10 ML | - | - |
| 2.02 | 5-FLUOROURACIL | 1 | 250 MG/5 ML | - | - |
| 33.01 to 3.02- ABEMACICLIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||
| 3.01 | ABEMACICLIB | 1 | 100 MG | - | - |
| 3.02 | ABEMACICLIB | 1 | 150 MG | - | - |
| 44.01 to 4.02- BOSUTINIB (QUOTING FOR ALL STRENGTH IS PREFERABLE, TECHNICALLY SHORTLISTED INNOVATORS/ORIGINALS , L1 & L2 WILL BE SELECTED BASED ON CONSOLIDATED RESULTS) | |||||
stage.html
html • 0.17 MB
tech_eval.pdf
boq_comp_chart.xlsx
xlsx
fin_eval.pdf
Tap a document below to read it instantly. You can also download everything as a ZIP if you prefer.
details.html
html • 0.04 MB
Tendernotice_1.pdf
PDF • 0.26 MB
TechsheetSchVI202527.xls
Additional Documents • 0.11 MB
TenderDocument.pdf
Tender Documents • 0.59 MB
BOQ_920059.xls
BOQ • 0.81 MB
CPP.pdf
PDF • 0.11 MB
Download all tender documents and submit your bid
Disclaimer: TenderKart has made every reasonable effort to ensure that the information on this page is accurate and authentic, however it cannot be held liable for any third-party claims or losses or any damages. TenderKart makes no warranty, expressed or implied, as to the results obtained from the use of this information. If you notice any error or omission, please let us know at [email protected].